KYTX

Kyverna is a clinical-stage cell-therapy company with no approved products and no product revenue in any year shown (FY2023–FY2025 revenue all blank). The 10-K states this plainly: 'We have no products approved for commercial sale, have never generated any revenue from product sales and may never be profitable.' Every dollar of value here rests on unapproved candidates clearing trials — the filing itself flags that 'our business depends entirely on the success of our product candidates' and that preclinical/early results 'may not be predictive of future trial results.' That is unknowable, binary risk, not a fundamentals story you can underwrite from the numbers provided.

The numbers make the risk acute rather than abstract. FY2025 net loss widened to -$161M (from -$127M in FY2024 and -$60.4M in FY2023 — losses have nearly tripled in two years), operating cash flow was -$154M, and R&D rose 18.9% to $134M as spend accelerates. Against that burn sits just $124M of cash. Even though cash grew 28.4% YoY, that balance covers under a year of operations — a genuine funding cliff. Management concedes it 'will require substantial additional capital' and may otherwise be 'forced to delay, reduce and/or eliminate' programs. ROE is -69.4% and the accumulated deficit has ballooned to -$425M.